CD8A and ovarian cancer: Moreover, the presence of dysfunctional (CD8+PD-1+) or terminally exhausted (CD8+PD-1+TOX+) T cells, along with their interactions with PD-L1+ cells, independently predicts 24-month progression-free survival (PFS) in dMMR uterine or ovarian cancer patients receiving nivolumab (32, 33).